Triheptanoin: A rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency

Sidharth Mahapatra, Amitha Ananth, Nancy Baugh, Mihaela Damian, Gregory M. Enns

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Carnitine-acylcarnitine translocase (CACT) deficiency is a rare long-chain fatty acid oxidation disorder (LC-FAOD) with high mortality due to cardiomyopathy or lethal arrhythmia. Triheptanoin (UX007), an investigational drug composed of synthetic medium odd-chain triglycerides, is a novel therapy in development for LC-FAOD patients. However, cases of its safe and efficacious use to reverse severe heart failure in CACT deficiency are limited. Here, we present a detailed report of an infant with CACT deficiency admitted in metabolic crisis that progressed into severe cardiogenic shock who was successfully treated by triheptanoin. The child was managed, thereafter, on triheptanoin until her death at 3 years of age from a cardiopulmonary arrest in the setting of acute respiratory illness superimposed on chronic hypercarbic respiratory failure.

Original languageEnglish (US)
Title of host publicationJIMD Reports
PublisherSpringer
Pages19-23
Number of pages5
DOIs
StatePublished - Jan 1 2018

Publication series

NameJIMD Reports
Volume39
ISSN (Print)2192-8304
ISSN (Electronic)2192-8312

Fingerprint

Carnitine Acyltransferases
Cardiogenic Shock
Fatty Acids
Investigational Drugs
Oxidation
Heart Arrest
Cardiomyopathies
Respiratory Insufficiency
Cardiac Arrhythmias
Triglycerides
Therapeutics
Heart Failure
Mortality
triheptanoin
Carnitine-Acylcarnitine Translocase Deficiency

Keywords

  • Cardiogenic shock
  • Carnitine-acylcarnitine translocase deficiency
  • Long-chain fatty acid oxidation disorder
  • Triheptanoin
  • UX007

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)

Cite this

Mahapatra, S., Ananth, A., Baugh, N., Damian, M., & Enns, G. M. (2018). Triheptanoin: A rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency. In JIMD Reports (pp. 19-23). (JIMD Reports; Vol. 39). Springer. https://doi.org/10.1007/8904_2017_36

Triheptanoin : A rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency. / Mahapatra, Sidharth; Ananth, Amitha; Baugh, Nancy; Damian, Mihaela; Enns, Gregory M.

JIMD Reports. Springer, 2018. p. 19-23 (JIMD Reports; Vol. 39).

Research output: Chapter in Book/Report/Conference proceedingChapter

Mahapatra, S, Ananth, A, Baugh, N, Damian, M & Enns, GM 2018, Triheptanoin: A rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency. in JIMD Reports. JIMD Reports, vol. 39, Springer, pp. 19-23. https://doi.org/10.1007/8904_2017_36
Mahapatra S, Ananth A, Baugh N, Damian M, Enns GM. Triheptanoin: A rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency. In JIMD Reports. Springer. 2018. p. 19-23. (JIMD Reports). https://doi.org/10.1007/8904_2017_36
Mahapatra, Sidharth ; Ananth, Amitha ; Baugh, Nancy ; Damian, Mihaela ; Enns, Gregory M. / Triheptanoin : A rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency. JIMD Reports. Springer, 2018. pp. 19-23 (JIMD Reports).
@inbook{b716b74dc022400894c2160d14b38b22,
title = "Triheptanoin: A rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency",
abstract = "Carnitine-acylcarnitine translocase (CACT) deficiency is a rare long-chain fatty acid oxidation disorder (LC-FAOD) with high mortality due to cardiomyopathy or lethal arrhythmia. Triheptanoin (UX007), an investigational drug composed of synthetic medium odd-chain triglycerides, is a novel therapy in development for LC-FAOD patients. However, cases of its safe and efficacious use to reverse severe heart failure in CACT deficiency are limited. Here, we present a detailed report of an infant with CACT deficiency admitted in metabolic crisis that progressed into severe cardiogenic shock who was successfully treated by triheptanoin. The child was managed, thereafter, on triheptanoin until her death at 3 years of age from a cardiopulmonary arrest in the setting of acute respiratory illness superimposed on chronic hypercarbic respiratory failure.",
keywords = "Cardiogenic shock, Carnitine-acylcarnitine translocase deficiency, Long-chain fatty acid oxidation disorder, Triheptanoin, UX007",
author = "Sidharth Mahapatra and Amitha Ananth and Nancy Baugh and Mihaela Damian and Enns, {Gregory M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/8904_2017_36",
language = "English (US)",
series = "JIMD Reports",
publisher = "Springer",
pages = "19--23",
booktitle = "JIMD Reports",

}

TY - CHAP

T1 - Triheptanoin

T2 - A rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency

AU - Mahapatra, Sidharth

AU - Ananth, Amitha

AU - Baugh, Nancy

AU - Damian, Mihaela

AU - Enns, Gregory M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Carnitine-acylcarnitine translocase (CACT) deficiency is a rare long-chain fatty acid oxidation disorder (LC-FAOD) with high mortality due to cardiomyopathy or lethal arrhythmia. Triheptanoin (UX007), an investigational drug composed of synthetic medium odd-chain triglycerides, is a novel therapy in development for LC-FAOD patients. However, cases of its safe and efficacious use to reverse severe heart failure in CACT deficiency are limited. Here, we present a detailed report of an infant with CACT deficiency admitted in metabolic crisis that progressed into severe cardiogenic shock who was successfully treated by triheptanoin. The child was managed, thereafter, on triheptanoin until her death at 3 years of age from a cardiopulmonary arrest in the setting of acute respiratory illness superimposed on chronic hypercarbic respiratory failure.

AB - Carnitine-acylcarnitine translocase (CACT) deficiency is a rare long-chain fatty acid oxidation disorder (LC-FAOD) with high mortality due to cardiomyopathy or lethal arrhythmia. Triheptanoin (UX007), an investigational drug composed of synthetic medium odd-chain triglycerides, is a novel therapy in development for LC-FAOD patients. However, cases of its safe and efficacious use to reverse severe heart failure in CACT deficiency are limited. Here, we present a detailed report of an infant with CACT deficiency admitted in metabolic crisis that progressed into severe cardiogenic shock who was successfully treated by triheptanoin. The child was managed, thereafter, on triheptanoin until her death at 3 years of age from a cardiopulmonary arrest in the setting of acute respiratory illness superimposed on chronic hypercarbic respiratory failure.

KW - Cardiogenic shock

KW - Carnitine-acylcarnitine translocase deficiency

KW - Long-chain fatty acid oxidation disorder

KW - Triheptanoin

KW - UX007

UR - http://www.scopus.com/inward/record.url?scp=85051116334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051116334&partnerID=8YFLogxK

U2 - 10.1007/8904_2017_36

DO - 10.1007/8904_2017_36

M3 - Chapter

C2 - 28689308

AN - SCOPUS:85051116334

T3 - JIMD Reports

SP - 19

EP - 23

BT - JIMD Reports

PB - Springer

ER -